Looking for:
Clotrimazole and betamethasone herpes. Betamethasone/Clotrimazole, Topical: References |
- Betamethasone/Clotrimazole, Topical - Tufts Medical Center Community Care
- Clotrimazole and betamethasone herpes
Drug information provided by: IBM Micromedex. Clotrimazole and betamethasone topical combination is used to treat fungus infections. Clotrimazole works by killing the fungus or preventing its growth. Betamethasone, a corticosteroid cortisone-like medicine or steroidis used to help relieve redness, swelling, itching, and other discomfort of fungus infections. There is a problem with information submitted for this request. Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID, plus expertise on managing health.
To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you. If you are a Mayo Clinic patient, this could include protected health information.
If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail. You'll soon start receiving the latest Mayo Clinic health information you requested in your inbox. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
This site complies with the HONcode standard for trustworthy health information: verify here. This content does not have an English version. This content does not have an Arabic version. See more conditions. Products and services. Thank you for subscribing! Sorry something went wrong with your subscription Please, try again in a couple of minutes Retry.
NEW — Man Overboard!
❾-50%}Clotrimazole and betamethasone herpes.
Help Accessibility Careers. Search term. Review published: CRD summary This review concluded that trifluridine, acyclovir and possibly interferon were effective for herpes simplex virus epithelial keratitis. Authors' objectives To systematically review randomised controlled trials for Herpes simplex virus epithelial and stromal keratitis in order to establish an evidence-based foundation for treatment. Study selection To be eligible for inclusion, studies had to be prospective, randomised, double-blinded, controlled, compare any treatment for Herpes simplex virus keratitis with any other treatment or placebo, use specific clinical criteria for diagnosis and outcomes and include a description of the statistical analysis used.
Assessment of study quality The authors did not state that they assessed validity. Data extraction The authors stated neither how the data were extracted for the review nor how many reviewers performed the data extraction. Methods of synthesis Data were synthesised narratively. Results of the review Thirty-seven studies met the inclusion criteria: 30 for Herpes simplex virus epithelial keratitis 1, participants and seven for stromal keratitis 1, participants.
Authors' conclusions The best evidence for the treatment of Herpes simplex virus epithelial keratitis supported the use of topical trifluridine and topical or oral acyclovir and suggested an additional benefit from topical interferon. CRD commentary The inclusion criteria appeared adequate. Implications of the review for practice and research Practice : The authors stated that the evidence supported use of topical trifluridine and topical or oral acyclovir for Herpes simplex virus epithelial keratitis and suggested an additional benefit from topical interferon.
Research : The authors did not state any implications for further research. AccessionNumber In this Page. Similar articles in PubMed. Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. Herpetic Eye Disease Study Group. Br J Ophthalmol. Review Therapeutic interventions for herpes simplex virus epithelial keratitis. Wilhelmus KR. Cochrane Database Syst Rev.
Epub Jan Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID, plus expertise on managing health. To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you.
If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail. You'll soon start receiving the latest Mayo Clinic health information you requested in your inbox.
All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below. This site complies with the HONcode standard for trustworthy health information: verify here.
This content does not have an English version. This content does not have an Arabic version. This site complies with the HONcode standard for trustworthy health information: verify here. This content does not have an English version. This content does not have an Arabic version. See more conditions. Products and services.
Thank you for subscribing! Sorry something went wrong with your subscription Please, try again in a couple of minutes Retry. NEW — Man Overboard!
Federal government websites often end in. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. NCBI Bookshelf. This review concluded that trifluridine, acyclovir and possibly interferon were effective for herpes simplex virus epithelial keratitis.
Corticosteroids with an antiviral were effective for Herpes simplex virus stromal keratitis and long-term acyclovir reduced recurrence. The validity of these conclusions may be limited by the small size of studies, restriction to articles published in English and the method of data extraction. To systematically review randomised controlled trials for Herpes simplex virus epithelial and stromal keratitis in order to establish an evidence-based foundation for treatment.
Search terms were reported. Reference lists of identified articles were searched. To be eligible for inclusion, studies had to be prospective, randomised, double-blinded, controlled, compare any treatment for Herpes simplex virus keratitis with any other treatment or placebo, use specific clinical criteria for diagnosis and outcomes and include a description of the statistical analysis used. The reported outcomes were healing defined by fluorescein or rose bengal staining, slit lamp evaluation and in one study, polymerase chain reaction for Herpes simplex virus DNA and viral culture.
Placebo was used in all trials, alone or in combination. Three reviewers independently determined the eligibility of each article for inclusion. Only studies uniformly agreed upon as meeting the criteria were included. The authors stated neither how the data were extracted for the review nor how many reviewers performed the data extraction. Data were synthesised narratively. Whether or not a significant difference was reported was extracted from each study.
Thirty-seven studies met the inclusion criteria: 30 for Herpes simplex virus epithelial keratitis 1, participants and seven for stromal keratitis 1, participants. The number of participants in each study ranged from 10 to There was no significant difference between groups in 20 of the 30 trials of Herpes simplex virus epithelial keratitis.
Acyclovir was superior to placebo, adenine arabinoside and idoxuridine one study each. In one study, acyclovir in combination with minimal wiping debridement was superior to minimal wiping debridement alone. Trifluridine was superior to adenine arabinoside and idoxuridine one trial each. Addition of human leukocyte interferon to acyclovir two trials and trifluridine and bromovinyl deoxyuridine one study each was superior to these agents alone.
There was no significant difference in two of the seven trials in Herpes simplex virus stromal keratitis. Betamethasone two trialsdexamethasone one trialflurbiprofen one trial in combination with acyclovir were superior to acyclovir alone. Acyclovir one trial and prednisone one trial were also superior to placebo. The best evidence for the treatment of Herpes simplex virus epithelial keratitis supported the use of topical trifluridine and topical or oral acyclovir and suggested an additional benefit from topical interferon.
The best evidence for the treatment of Herpes simplex virus stromal keratitis supported the use of topical corticosteroids given with a prophylactic antiviral. Long-term suppressive oral acyclovir therapy appeared to reduce the incidence of recurrent Herpes simplex virus keratitis. The inclusion criteria appeared adequate. However, the search of only one database may have missed relevant studies and the restriction to studies published in English could have introduced language bias.
Validity was not formally assessed and limited details of included studies were reported, which made it difficult to assess the quality of the evidence on which the review findings were based. A narrative synthesis was appropriate, but the synthesis provided was of limited usefulness as conclusions were based on individual studies, most of which had a small number of participants. These limitations made the reliability of the authors' conclusions uncertain.
Practice : The authors stated that the evidence supported use of topical trifluridine and topical or oral acyclovir for Herpes simplex virus epithelial keratitis and suggested an additional benefit from topical interferon. The evidence for the treatment of Herpes simplex virus stromal keratitis supported topical corticosteroids given together with a prophylactic antiviral and long-term suppressive oral acyclovir therapy to reduce the incidence of recurrent Herpes simplex virus keratitis.
Evidence-based treatment of herpes simplex virus keratitis: a systematic review. Ocular Surface ; 5 3 : This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE.
Each critical abstract contains a brief summary of the review methods, results and conclusions followed by a detailed critical assessment on the reliability of the review and the conclusions drawn. Turn recording back on. Help Accessibility Careers.
Search term. Review published: CRD summary This review concluded that trifluridine, acyclovir and possibly interferon were effective for herpes simplex virus epithelial keratitis. Authors' objectives To systematically review randomised controlled trials for Herpes simplex virus epithelial and stromal keratitis in order to establish an evidence-based foundation for treatment.
Study selection To be eligible for inclusion, studies had to be prospective, randomised, double-blinded, controlled, compare any treatment for Herpes simplex virus keratitis with any other treatment or placebo, use specific clinical criteria for diagnosis and outcomes and include a description of the statistical analysis used. Assessment of study quality The authors did not state that they assessed validity. Data extraction The authors stated neither how the data were extracted for the review nor how many reviewers performed the data extraction.
Methods of synthesis Data were synthesised narratively. Results of the review Thirty-seven studies met the inclusion criteria: 30 for Herpes simplex virus epithelial keratitis 1, participants and seven for stromal keratitis 1, participants. Authors' conclusions The best evidence for the treatment of Herpes simplex virus epithelial keratitis supported the use of topical trifluridine and topical or oral acyclovir and suggested an additional benefit from topical interferon.
CRD commentary The inclusion criteria appeared adequate. Implications of the review for practice and research Practice : The authors stated that the evidence supported use of topical trifluridine and topical or oral acyclovir for Herpes simplex virus epithelial keratitis and suggested an additional benefit from topical interferon. Research : The authors did not state any implications for further research. AccessionNumber In this Page. Similar articles in PubMed.
Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. Herpetic Eye Disease Study Group. Br J Ophthalmol. Review Therapeutic interventions for herpes simplex virus epithelial keratitis. Wilhelmus KR. Cochrane Database Syst Rev. Epub Jan Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis.
Review Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Epub Dec 8. Recent Activity. Clear Turn Off Turn On. Follow NCBI.
Clotrimazole works by killing the fungus or preventing its growth. Betamethasone, a corticosteroid (cortisone-like medicine or steroid), is used. However, if you think it's herpes, watch out!the topical you are using has an antifungal agent and a steroid that suppresses the immune system. However, if you think it's herpes, watch out!the topical you are using has an antifungal agent and a steroid that suppresses the immune system. Corticosteroids with an antiviral were effective for Herpes simplex virus acyclovir was used in six trials (3% or mg orally), betamethasone (two. This combination medication is used to treat a variety of inflamed fungal skin infections such as ringworm, athlete's foot, and jock itch. Data extraction The authors stated neither how the data were extracted for the review nor how many reviewers performed the data extraction. If you are a Mayo Clinic patient, this could include protected health information. Long-term suppressive oral acyclovir therapy appeared to reduce the incidence of recurrent Herpes simplex virus keratitis.Drug information provided by: IBM Micromedex. In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:. Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals.
For non-prescription products, read the label or package ingredients carefully. Use of clotrimazole and betamethasone topical combination cream is not recommended in children younger than 17 years of age. Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of clotrimazole and betamethasone topical combination in the elderly.
However, elderly patients are more likely to have a thinning skin or skin ulcers, which may require caution in patients receiving clotrimazole and betamethasone topical combination. Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur.
In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below.
The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive. Using this medicine with any of the following medicines is not recommended.
Your doctor may decide not to treat you with this medication or change some of the other medicines you take. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases.
If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur.
Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:. There is a problem with information submitted for this request. Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID, plus expertise on managing health. To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you.
If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail.
You'll soon start receiving the latest Mayo Clinic health information you requested in your inbox. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
This site complies with the HONcode standard for trustworthy health information: verify here. This content does not have an English version. This content does not have an Arabic version. See more conditions. Products and services. Before Using Drug information provided by: IBM Micromedex In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. Thank you for subscribing!
Sorry something went wrong with your subscription Please, try again in a couple of minutes Retry. NEW — Man Overboard!
No comments:
Post a Comment